A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2017
At a glance
- Drugs Paricalcitol (Primary) ; Pembrolizumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 09 Nov 2017 New trial record
- 03 Nov 2017 Planned primary completion date changed from 15 Nov 2018 to 15 Dec 2018.
- 03 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 1 Dec 2017.